Search clinical trials for: Second Line

Total 22710 results

Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Investigational Agents for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Small Cell Lung Carcinoma

Poland, Russian Federation, United States, Australia, Austria, Canada, Hungary, Israel, Italy, Korea, Republic of, Spain, Switzerland
National Cancer Institute (NCI)

Active, not recruiting

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7

United States
Amgen

Active, not recruiting

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

Atherosclerotic Cardiovascular Disease

United States, Belgium, Spain, China, Korea, Republic of, Australia, Netherlands, Austria, Czechia, Taiwan, Italy, Portugal, Greece, Hong Kong, Hungary, United Kingdom, France, Bulgaria, Germany, Finland, Japan, Sweden, Canada, Denmark, Icelan... and more
NuCana plc

Active, not recruiting

A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

Colorectal Neoplasms | Colorectal Cancer | Colorectal Cancer Metastatic | Colorectal Adenocarcinoma | Neoplasm, Colorectal

United States, Spain, United Kingdom, Italy, Germany, France
The First Hospital of Jilin University

Completed

Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Heinrich-Heine University, Duesseldorf
Servier

Completed

Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma (TRITICC)

Cholangiocarcinoma

Germany
Agenus Inc.
GOG Foundation

Active, not recruiting

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

Cervical Cancer

United States, Korea, Republic of, Taiwan, Brazil, Mexico, Peru, Thailand
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-line NSCLC (JAVELIN Lung 100)

First Line Non-Small Cell Lung Cancer

Spain, United States, Hungary, Israel, China, Korea, Republic of, Taiwan, Czechia, Russian Federation, Australia, Brazil, Lebanon, Serbia, Thailand, Canada, Slovakia, Ukraine, Bulgaria, Italy, Netherlands, New Zealand, Poland, Belgium, Turk... and more
SWOG Cancer Research Network
National Cancer Institute (NCI); Cancer Prevention Pharmaceuticals, Inc.

Active, not recruiting

S0820, Adenoma and Second Primary Prevention Trial (PACES)

Colorectal Neoplasms

United States
Rigel Pharmaceuticals

Terminated

Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

Immune Thrombocytopenia | ITP

United States
Sunnybrook Health Sciences Centre

Active, not recruiting

A Mindful Self-compassion Based Intervention for Specialist Rehabilitation Providers

Burnout, Professional | Secondary Traumatic Stress | Compassion Fatigue

Canada
University of Pennsylvania

Active, not recruiting

Pharmacogenetic-guided Choice of Post-surgery Analgesics (PRECISE)

Acute Pain | Post Operative Pain

United States
Intergroupe Francophone de Cancerologie Thoracique

Active, not recruiting

Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE)

Non Small Cell Lung Cancer Metastatic

France
Novartis Pharmaceuticals

Terminated

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E)

Carcinoma, Non-Small-Cell Lung

Japan, Korea, Republic of, Singapore
Cardiff Oncology

Completed

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation

Metastatic Colorectal Cancer | KRAS Gene Mutation

United States
Åslaug Helland
Bristol-Myers Squibb; Oslo University Hospital; Ultimovacs ASA

Active, not recruiting

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU)

Cancer | Mesothelioma | Mesotheliomas Pleural | Cancer of Lung | Cancer, Lung | Mesothelioma; Pleura | Mesothelioma; Lung

Norway, Denmark, Sweden, Spain, Australia
The HIV Netherlands Australia Thailand Research...
Khon Kaen University

Active, not recruiting

A Prospective Cohort of Children With HIV Infection

HIV Infections

Thailand
Bayer

Terminated

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke (OCEANIC-AF)

Atrial Fibrillation | Prevention of Stroke or Systemic Embolism

Canada, United States, Israel, Korea, Republic of, China, Taiwan, Belgium, Australia, Singapore, Malaysia, Slovakia, United Kingdom, Czechia, Latvia, Japan, Brazil, Lithuania, Germany, France, Sweden, Turkey, Switzerland, Estonia, Bul... and more
Novartis Pharmaceuticals

Completed

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (BioItaLEE)

Breast Cancer

Italy
Latin American Cooperative Oncology Group
Pfizer

Completed

Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer (LACOG1018)

Ovarian Cancer

Brazil
Rose Research Center, LLC
Foundation for a Smoke Free World INC

Active, not recruiting

Evaluate Harm Reduction Products as a Second Line Intervention for Adult Smokers Who Do Not Quit With NRT

Smoking Cessation | Harm Reduction

United States
Cardiff Oncology

No longer available

Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | KRAS Gene Mutation
Institute of Hematology & Blood Diseases Hospital...

Terminated

Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment (BID-PERAL)

Acquired Pure Red Cell Aplasia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Locally Advanced or Metastatic and Unresectable HCC

United States, Spain, China, Taiwan, Belgium, Korea, Republic of, Italy, Hong Kong, Russian Federation, Ukraine, Turkey, Poland, Germany
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Urothelial Carcinoma

Hungary, United States, Argentina, Australia, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
Colgate Palmolive

Completed

Clinical Research Study to Evaluate the Stain Removal Efficacy

Tooth Stain Removal

Puerto Rico
Menoufia University

Completed

Docetaxel and Irinotecan in Gastric Cancer

Stomach Cancer | Gastric Cancer | Chemotherapy Effect

Egypt
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)

Carcinoma, Renal Cell

United States, Australia, Canada, Chile, France, Hungary, Israel, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, United Kingdom
Amgen

Completed

A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

Atherosclerotic Cardiovascular Disease

Canada, United States, Belgium, Spain, China, Korea, Republic of, Australia, Netherlands, Austria, Czechia, Taiwan, Hungary, Italy, Portugal, United Kingdom, Greece, Hong Kong, Turkey, France, Bulgaria, Germany, Finland, Japan, Sweden, ... and more
St. Pölten University of Applied Sciences
Karl Landsteiner University of Health Sciences; Austrian Health Insurance Fund

Active, not recruiting

Improving Glycaemic Control in Patients With Type 2 Diabetes Mellitus Through Peer Support Instant Messaging (DiabPeerS)

Diabetes Mellitus, Type 2 | Peer Support | Instant Messaging Service

Austria
Cardiff Oncology

Active, not recruiting

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Metastatic Colorectal Cancer | Colorectal Cancer

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Metastatic Malignant Neoplasm in the Liver | Metastatic Breast Carcinoma | Metastatic Malignant Neoplasm in the Lung and other conditions

United States, Canada, Saudi Arabia, Korea, Republic of
Wuhan Union Hospital, China

Withdrawn

Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer (XHZL)

Colorectal Cancer | Chemotherapy | Angiogenesis
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia... and other collaborators

Active, not recruiting

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (SOFT)

Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States, Canada, Switzerland
BeiGene

Completed

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)

Spain, United States, United Kingdom, China, Taiwan, Korea, Republic of, Japan, France, Germany, Belgium, Italy
Institut für Klinische Krebsforschung IKF GmbH...
Johann Wolfgang Goethe University Hospital, Prof. Dr. med. Trojan

Active, not recruiting

Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function

Hepatocellular Carcinoma (HCC) | Second Line Treatment

Germany
Canadian Cancer Trials Group
Pfizer

Completed

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Breast Cancer

Canada
Juno Therapeutics, a Subsidiary of Celgene

Completed

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, Nonhodgkin

United States
Pfizer

Completed

A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

Breast Cancer | Breast Neoplasms | Breast Tumors | Breast Carcinoma | Cancer of Breast

India
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Deep Vein Thrombosis | Pulmonary Embolism | Metastatic Malignant Solid Neoplasm | Cerebral Vein Thrombosis | Splanchnic Vein Thrombosis

United States
Bristol-Myers Squibb

Withdrawn

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone (SUPPRESS)

HIV

United States
Imperial College London
Royal Brompton & Harefield NHS Foundation Trust

Completed

Reverse Remodelling and Remission Markers in the Serial Evaluation of Recent-onset Dilated Cardiomyopathy (REMIT-DCM)

Dilated Cardiomyopathy

United Kingdom
Federation Francophone de Cancerologie Digestive
Shire

Active, not recruiting

Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma (OESIRI)

Squamous Cell Carcinoma

France
Hellenic Institute for the Study of Sepsis

Completed

Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection (BEYOND)

Mortality | Clostridioides Difficile Infection | Organ Dysfunction Syndrome | Stool Microbiome | Clostridioides Difficile Infection Recurrence

Greece
University of Miami
Pfizer

Completed

Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

Ulcerative Colitis

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Edwards Lifesciences

Terminated

Edwards Cardioband System ACTIVE Pivotal Clinical Trial (ACTIVE) (ACTIVE)

Mitral Regurgitation | Mitral Insufficiency | Functional Mitral Regurgitation

United States
Cardiff Oncology

Active, not recruiting

Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma

United States
Chinese PLA General Hospital
The Second Hospital of Hebei Medical University; Air Force Military Medical... and other collaborators

Completed

First Line Therapy for High Risk Acute GVHD

Stem Cell Transplant Complications | aGVHD

China
Sun Yat-sen University

Enrolling by invitation

Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using MR Guided Linear Accelerator

Rectal Cancer

China

Search clinical trials for: Second Line

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations